27 completed. 21 Phase 1, 6 Phase 2.
By phase and status
Follow AZD1656: new trials by email Literature Review of AZD1656 trials Research Report on AZD1656
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|
AZD1656 in Diabetic Patients Hospitalised With Suspected or Confirmed COVID-19
AZD1656, Placebo - Covid19 | Phase 2 | Completed | St George Street Capital | 170 | 2020-08-12 | 2022-04-25 |
AZD1656 in Transplantation With Diabetes tO PromoTe Immune TOleraNce
AZD1656, Placebo - Type 2 Diabetes, Diabetes Mellitus, Type 2 | Phase 2 | Completed | Queen Mary University of London | 26 | 2019-12-13 | 2024-06-20 |
A Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics After High Single Ascending Oral Doses of AZD1656 in T2DM Patients
AZD1656, Placebo - Type 2 Diabetes Mellitus | Phase 1 | Completed | AstraZeneca | 24 | 2010-10-01 | 2011-02-17 |
A Relative Bioavailability Study Measuring the Extent and Rate of Absorption of Different Tablet Formulations of AZD1656 in Type 2 Diabetes Mellitus (T2DM) Patients
AZD1656 - Type 2 Diabetes Mellitus, High Blood Sugar | Phase 1 | Completed | AstraZeneca | 20 | 2010-09-01 | 2012-01-19 |
Investigate the Effect of AZD1656 on the Pharmacokinetics of Digoxin in Type 2 Diabetes Mellitus Patients
AZD1656, Digoxin, Placebo - Type 2 Diabetes Mellitus | Phase 1 | Completed | AstraZeneca | 20 | 2010-06-01 | 2011-01-05 |
Japan Dose Regimen Study of AZD1656 in Japanese Type 2 Diabetes Mellitus Patients
AZD1656, Placebo - Type 2 Diabetes Mellitus | Phase 2 | Completed | AstraZeneca | 224 | 2010-05-01 | 2012-08-27 |
Investigate the Effect of AZD1656 on the Pharmacokinetics and Pharmacodynamics of Warfarin in Type 2 Diabetes Mellitus (T2DM) Patients
Warfarin, Placebo, AZD1656 - Type 2 Diabetes Mellitus | Phase 1 | Completed | AstraZeneca | 16 | 2010-04-01 | 2010-11-08 |
To Evaluate the Effect of Gemfibrozil on the Pharmacokinetics and Pharmacodynamics of a Single Dose of AZD1656
AZD1656, Gemfibrozil, Placebo - Type 2 Diabetes Mellitus | Phase 1 | Completed | AstraZeneca | 19 | 2010-03-01 | 2010-07-01 |
Investigate the Effect of AZD1656 on the Pharmacokinetics of Sitagliptin in Patients With Type 2 Diabetes Mellitus
AZD1656, Sitagliptin - Type 2 Diabetes Mellitus | Phase 1 | Completed | AstraZeneca | 12 | 2010-03-01 | 2010-07-01 |
Study To Assess the Pharmacokinetics of AZD1656 During Coadministration With Simvastatin
AZD1656, simvastatin - Type 2 Diabetes Mellitus | Phase 1 | Completed | AstraZeneca | 44 | 2010-03-01 | 2010-11-08 |
To Assess the Pharmacokinetics of AZD1656 and Its Metabolite in Type 2 Diabetes Mellitus Patients
AZD1656 - Glucose Lowering | Phase 1 | Completed | AstraZeneca | 21 | 2010-03-01 | 2010-12-09 |
Investigate the Effect of AZD1656 on the Pharmacokinetics of Pioglitazone and Vice Versa in Type 2 Diabetes Mellitus
AZD1656, Pioglitazone - Type 2 Diabetes Mellitus | Phase 1 | Completed | AstraZeneca | 28 | 2010-02-01 | 2010-07-12 |
Safety and Tolerability of AZD1656 in Type 2 Diabetes Mellitus (T2DM) Patients Treated With Metformin and Sulfonylurea
AZD1656, Placebo - Type II Diabetes Mellitus | Phase 1 | Completed | AstraZeneca | 75 | 2009-10-01 | 2010-02-26 |
Evaluate Efficacy, Safety and Tolerability of AZD1656 as Add-on Treatment to Metformin in Type 2 Diabetes Mellitus (TD2M) Patients
AZD1656, Placebo, Glipizide - Type II Diabetes Mellitus | Phase 2 | Completed | AstraZeneca | 530 | 2009-10-01 | 2012-11-26 |
Study to Assess the Absorption, Distribution, Metabolism and Excretion of AZD1656 in Type 2 Diabetes Mellitus (T2DM)
AZD1656 - Type II Diabetes Mellitus | Phase 1 | Completed | AstraZeneca | 6 | 2009-07-01 | 2009-09-16 |
To Study Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD1656 in Japanese Type 2 Diabetes Mellitus (T2DM) Patients
AZD1656, Placebo - Type 2 Diabetes | Phase 1 | Completed | AstraZeneca | 24 | 2009-05-01 | 2009-11-03 |
Safety and Tolerability After Four Weeks of Treatment With AZD1656 in Patients With Type 2 Diabetes
AZD1656, Placebo - Type II Diabetes | Phase 2 | Completed | AstraZeneca | 20 | 2009-02-01 | 2012-12-06 |
To Evaluate the Response to Glucagon During Hypoglycemia
AZD1656, Glucagon - Type 2 Diabetes | Phase 1 | Completed | AstraZeneca | 8 | 2009-02-01 | 2009-05-07 |
Study to Assess the Safety and Tolerability After Multiple Oral Doses of AZD1656 in Patients With Type 2 Diabetes Mellitus Treated With Metformin
AZD1656, Placebo - Type 2 Diabetes | Phase 2 | Completed | AstraZeneca | 27 | 2009-01-01 | 2012-11-16 |
To Evaluate 24-hr Glucose After OD vs BD AZD1656
AZD1656 - Type II Diabetes | Phase 1 | Completed | AstraZeneca | 36 | 2009-01-01 | 2009-05-07 |
Showing 20 of 27. Sign in to see all of them.
Conditions studied
Diabetes Mellitus, Type 2 (22) · Diabetes Mellitus (6) · COVID-19 (1) · Diabetes Mellitus, Type 1 (1) · Hyperglycemia (1) · Hypoglycemia (1) · Kidney Failure, Chronic (1) · Maturity-Onset Diabetes of the Young, Type 2 (1)
Sponsors
AstraZeneca (25) · Queen Mary University of London (1) · St George Street Capital (1)
Countries
United States (19) · United Kingdom (4) · Germany (2) · Japan (2) · Romania (2) · Sweden (2) · Chile (1) · Czechia (1) · Hungary (1) · India (1) · Latvia (1) · Lithuania (1) · Mexico (1) · Peru (1) · Poland (1)
Top investigators
Mirjana Kujacic (6) · Stanko Skrtic (6) · Marcus Hompesch, MD (4) · Klas Malmberg, MD, PhD (3) · Klas Malmberg, MD, PhD, Prof (3) · Klas Malmberg, MD, PhD, Prof., (3) · Christoph Kapitza (2) · Emanuel P DeNoia, M.D (2) · Klas Malmberg, MD, PhD, Prof. (2) · Linda Morrow, MD (2) · Aslak Rautio (1) · Dr Emanuel DeNoia, MD (1) · Elaine Watkins, DO (1) · Emanuel P DeNoia, MD (1) · Emeline Ramos, MD (1)
Results publications
PMID 22943931, PMID 23522182, PMID 34853102, PMID 35996565